Abstract: Objective The aim of this study is to investigated the iodide uptake ability of iodide in glioma tumor,lung cancer and thyroid cancer cell lines after co- transfered the human sodium/iodide symporter and the human thyroperoxidase gene. Methods Through cloning, recombination, packaging and amplifying, the recombinant adenosine virus AdTPO was constructed. After purification. After transfected hNIS gene into tumor cell lines through liposome, stably expressing hNIS gene cell lines selected by G418 antibiotics was determined as control group. Using AdTPO, hTPO gene was transducted into control group cell lines, as experimental group. Tumor cell lines without hTPO and hNIS gene was applied as blank control group. Then, we investigated the 125I uptake assay and 125I influx experiments with glioma tumor,lung cancer and thyroid cancer cell lines. Results We were successful in co-transfecting hNIS and hTPO gene into human tumor cell lines, 125I uptakes and effective half life in experimental group was linger than control groups cell lines .After co-transfecting hNIS and hTPO gene, the uptake ability of 125I was 59628 1281,79638 1261,52971 2162and 49638 1281 counts·min-1 in H460, U251, ARO and FRO tumor cell lines. Conclusion The uptake ability of 125I could increase by co-transfection with hNIS and hTPO genes into human tumor cell lines.

Key words: Human sodium/ iodide symporter, Thyroperoxidase, Gene therapy, Radionuclide therapy, Recombinant adenovirus